February 2013 Blog Posts (10)

Exercise Linked to Decreased Risk for Certain Molecular Subtype of Colorectal Cancer

An increasing body mass index was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

Research has shown that dysregulation of the WNT/β-catenin (CTNNB1)…


Added by Peter Hofland, PhD on February 26, 2013 at 3:00pm — No Comments

Ado-trastuzumab Emtansine, a New Targeted Medicine, Gives Patients a Survival Advantage: First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer

On February 22nd, 2013, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla™, Genentech), as a single medicine, for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with trastuzumab (Herceptin®, Genentech) and a taxane chemotherapy. The newly approved drug is the…


Added by Peter Hofland, PhD on February 23, 2013 at 5:00pm — No Comments

Biomarker May Identify Neuroblastomas With Sensitivity to BET Bromodomain Inhibitors

Neuroblastoma is commonly used to refer to a spectrum of neuroblastic tumors, including neuroblastomas, ganglioneuroblastomas, and ganglioneuromas, that arise from primitive sympathetic ganglion cells. The disease is the third most common childhood cancer, after leukemia and brain tumors, and is the most common solid extracranial tumor in children. Each year more than 600 cases are diagnosed in the United States each where it accounts for approximately 15% of all pediatric cancer…


Added by Peter Hofland, PhD on February 21, 2013 at 9:00pm — No Comments

Collaboration Starts on the Develop New Companion Tests for Investigational Leukemia Therapy

Earlier today, Abbott, Janssen Biotech and Pharmacyclics announced that they will collaborate in the development of a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.

The new companion test will be based on Abbott's proprietary fluorescence in situ hybridization (FISH) technology. With the FISH technology,…


Added by Editorial Team on February 21, 2013 at 6:30am — No Comments

Research Group Estimates Breast Biopsy Device Market to Grow Steadily to Reach U.S. $ 490 Million By 2017

Market analysts at Millennium Research Group say that the growing demographic at risk for breast cancer and increasing compliance with screening programs will spur demand for breast biopsies. Additionally, patients and clinicians are showing a growing preference for minimally invasive biopsies over open surgical alternatives. As a result, sales of breast biopsy devices used in these procedures will expand at a steady pace through…


Added by Editorial Team on February 21, 2013 at 5:30am — No Comments

Combination of EGFR and COX-2 Inhibitors may Prevent Head and Neck Cancer in High-risk Patients

A new drug combination including an EGFR and COX-2 Inhibitors shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal of the American Association for Cancer…


Added by Peter Hofland, PhD on February 19, 2013 at 8:00pm — No Comments

Bendamustine (Levact®) Plus Rituximab Doubles Progression-Free Survival in Patients with Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Compared with CHOP-R

Results from the StiL NHL-1 study published in The Lancet earlier today show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP-R), in newly diagnosed patients with indolent…


Added by Editorial Team on February 19, 2013 at 5:00pm — No Comments

Leukemia & Lymphoma Society Launches Unique "Someday is Today" Campaign

In 1962 only 4% of children with acute lymphoblastic leukemia (ALL) survived. Today, thanks to many treatment advances, the survival rate for pediatric patients with childhood ALL is 94%. Especially between 1975 and 2002, childhood cancer mortality decreased dramatically. Overall childhood cancer survival increased by 50%, while, at the same time 5-year survival rate for ALL increased from 60% to 89% for children younger than 15 years and from 28% to 50% for adolescents aged 15 to 19…


Added by Editorial Team on February 19, 2013 at 5:00pm — No Comments

MicroRNA Molecule miR-7 Suppressed KLF4 Expression in Highly Metastatic Cancer Stem-like Cells.

Despite significant improvement in survival rates of patients with breast cancer, the prognosis of metastatic disease is still dismal. Cancer stem-like cells (CSC) are considered to play a role in metastatic progression of breast cancer; however, the exact pathologic role of these cancer stem-like cells is still unclear. Now, for the first time, researchers from the University of Mississippi Medical Center in Jackson, Miss, have identified…


Added by Peter Hofland, PhD on February 5, 2013 at 10:30am — No Comments

Phase I Trial of High-dose Vorinostat may Lead the Way to Effective Treating of Relapsed Lymphomas

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease. Reporting the results of a first-of-its-kind phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by researchers from the Fred Hutchinson Cancer Research Center found that giving patients high doses of Vorinostat (suberoylanilide hydroxamic…


Added by Peter Hofland, PhD on February 4, 2013 at 10:00pm — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+